Some source checks need review. Dated summaries and references remain below. Confirm current guidance with the original source and your care team.
Decide which outcome matters to you
Lifespan means how long someone lives. Here, healthspan means years of better health and function. A trial about a lab value, symptoms, walking ability, disease events or survival answers different questions. Start with the outcome you actually care about before interpreting a longevity claim.
Sources: [1]
What a biological-age test can and cannot tell you
Biological-age tests use different measurements and models, so the phrase does not describe one standardized test. A result may be associated with health risks or may change over time, but that does not automatically make it a validated tool for choosing treatment or measuring treatment success. Ask what the test measures, how reproducible it is, which population it was studied in, and whether changing the result has been shown to change a meaningful health outcome. A telomere or clock result should not be read as a countdown or a personal lifespan forecast.
Look beyond a promising biomarker
A biomarker is a measured biological signal. FDA distinguishes those signals from clinical outcomes, such as how people feel, function or survive. Treating a marker as a substitute needs evidence for that particular use. For a peptide claim, check the human outcome, comparison group, follow-up and uncertainty. A changed lab value alone does not show longer or healthier life.
Sources: [1]
Other approaches remain research questions
This source check needs review. Confirm current guidance and the exact product or care route with the original source before relying on this dated summary. This dated summary provides background on the comparison.
Dated source summary
Rapamycin, metformin, senolytics, cell-based interventions and exosomes are distinct approaches, not one treatment category. Research activity does not establish a proven longevity treatment, and evidence for one compound cannot be transferred to another. A human review of rapamycin and related drugs describes a limited and mixed evidence base across health systems; it does not establish broad lifespan extension. Cell and exosome interventions require separate attention to the exact product and intended use. This guide does not provide a regimen or recommend using any of these approaches for aging.
Where to go next
Sources and dates
The source date describes the original material; the review date records our check. A dated source summary is not continuous monitoring, product testing or confirmation of current purchase terms.
- [1]FDA: Surrogate endpoints and clinical outcomes · Source date: Date not stated in accessed page · Reviewed
A biomarker is not automatically a validated substitute for how people feel, function or survive. Validation is specific to the intended context.
- [2]Concordance between changes in epigenetic clocks and changes in clinical outcomes in geroscience intervention trials: A systematic review · Source date: 2026 · Reviewed
Recent review, abstract only; methods, study-level risk of bias and certainty could not be checked. Do not imply all biological-age tests are equivalent; the conclusion is specific to studied epigenetic clocks/interventions.
- [3]Targeting ageing with rapamycin and its derivatives in humans: a systematic review · Source date: 2024 · Reviewed
Systematic review abstract, not direct primary evidence; no full appraisal. This is brief context only, not a recommendation. No equivalent evidence claim made for metformin, cell therapies, exosomes, or all senolytics.
- [4]FDA: Unapproved regenerative medicine therapies · Source date: June 3, 2021 · Reviewed
FDA warning about unapproved regenerative products and research oversight. No blanket claim about the entire current approved-cell-product inventory.
Designing Longevity is a founder-led editorial publication. Our content is not medically reviewed.
See a problem or outdated information? Tell us.